直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Federal Circuit IP Blog

Federal Circuit Faults Defendant for Gamesmanship for Presenting Untimely Noninfringement Theory Based on Lack of Data it Blocked in Discovery

October 22, 2025

Authored and Edited by Luke H. MacDonald, Ph.D.; Sonja W. Sahlsten

In Magēmā Technology LLC v. Phillips 66, No. 2024-1342 (Fed. Cir. Sept. 8, 2025) the Federal Circuit reversed denial of a motion for a new trial after the defendant argued it needed testing data to prove infringement when it had previously represented that testing data would be too dangerous to obtain.

Magēmā alleged Phillips’ refineries infringed a patent relating to desulfurizing heavy marine fuel oil (HMFO) to comply with international sulfur content standards. Right before jury selection, Phillips introduced a new noninfringement theory by arguing Magēmā could not prove infringement without actual product testing data. Magēmā timely objected, contending Phillips had prevented Magēmā from accessing testing data because, during discovery, Phillips argued it would be too dangerous to obtain. The judge overruled the objection, Phillips presented its theory, and the jury found for Phillips.

The court subsequently denied Magēmā’s motion for a new trial, finding Phillips’ new theory improper and prejudicial, but harmless.

The Federal Circuit reversed and remanded for a new trial, holding the new theory not harmless. Because the jury’s verdict did not specify its reasoning, the Court could not be reasonably certain it was untainted by Phillips’ improper and untimely theory. The Court instructed that Phillips may not argue on remand that it needs testing data for infringement.

The Court also affirmed the district court’s construction of “HMFO,” holding the specification “clearly and expressly” defines it, and rejected Phillips’ alternative grounds for affirmance of the verdict.

Tags

patent infringement, claim construction

Related Practices

Appeals, Issues, and Legal Strategy

Federal Circuit and Supreme Court Appeals

Global IP Enforcement, Litigation, and Trials

Patent Litigation and Trials

Related Industries

Energy

Oil and Gas

Related Offices

Reston, VA

Washington, DC

Contacts

Luke H. MacDonald, Ph.D.
Associate
Reston, VA
+1 571 203 2742
Email
Sonja W. Sahlsten
Partner
Washington, DC
+1 202 408 4329
Email

Copyright © Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information. 

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Lecture

Munich Licensing Summer Course 2026

June 18-19, 2026

Munich

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

Reception

12th Annual Georgia Asian Pacific American Bar Association Gala

May 21, 2026

Atlanta

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Webinar

Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement

May 18, 2026

Webinar

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP